<DOC>
	<DOC>NCT02022930</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of Hydros-TA Joint Therapy for relief of pain due to OA of the knee. Hydros-TA is designed to provide fast acting and long lasting pain relief for up to six months with a single IA injection.</brief_summary>
	<brief_title>Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Have radiographic evidence within the prior 6 months, as shown in the radiology reports, of OA grade 2 or 3 using KellgrenLawrence Grading for OA. Symptoms in the index knee for at least 12 months. Fully ambulatory Subject (ability to perform a 15 meters walk test). Male and female Subjects 40 through 85 years of age. BMI &gt;40 kg Secondary OA (acute knee injury, rheumatoid arthritis, gout, history of joint infection, osteonecrosis, chronic fibromyalgia) or other chronic autoimmune disease. Intra articular steroid therapy in last 3 months Intra articular viscosupplementation in last 6 months</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
</DOC>